
Opinion|Videos|February 2, 2026
Role of APPs in Shared Decision-Making in Alzheimer Disease
Author(s)Ken Cohen, MD, FACP
Panelists discuss how APPs strengthen shared decision-making through education and compassionate communication.
Advertisement
Episodes in this series

Panelists discuss how shared decision-making is vital for empowering patients and caregivers. Advance practice providers (APPs) act as educators who translate complex medical information into understandable terms, supporting informed consent.
Panelists discuss how empathy and communication skills enable APPs to align treatment goals with patient preferences and quality-of-life priorities. Continuous dialogue fosters trust and sustained engagement.
Panelists discuss how APPs ensure ongoing support throughout the disease journey, helping patients revisit decisions as conditions evolve.
Advertisement
Related to this article

Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.
Advertisement
Advertisement
Trending on AJMC
1
Complicated UTI Care Strained by Unclear Goals, Access Gaps
2
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
3
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
4
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
5

